Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study
Winchester Medical Center · Icahn School of Medicine at Mount Sinai · +123 more institutions
Abstract
Pulsed field ablation (PFA) is an emerging technology for the treatment of atrial fibrillation (AF), for which pre-clinical and early-stage clinical data are suggestive of some degree of preferentiality to myocardial tissue ablation without damage to adjacent structures. Here in the MANIFEST-17K study we assessed the safety of PFA by studying the post-approval use of this treatment modality. Of the 116 centers performing post-approval PFA with a pentaspline catheter, data were received from 106 centers (91.4% participation) regarding 17,642 patients undergoing PFA (mean age 64, 34.7% female, 57.8% paroxysmal AF and 35.2% persistent AF). No esophageal complications, pulmonary vein stenosis or persistent phrenic…
Citation impact
- FWCI
- 144.70
- Percentile
- 100%
- References
- 49
Authors
139- EEEmmanuel EkanemCorresponding
Winchester Medical Center, Icahn School of Medicine at Mount Sinai
- PNPetr Neužil
Na Homolce Hospital
- TRTobias Reichlin
University of Bern, University Hospital of Bern
- JKJ Kautzner
Institute of Clinical and Experimental Medicine
- PVPepijn van der Voort
Radboud University Nijmegen, Catharina Ziekenhuis
Topics & keywords
- Atrial fibrillation
- Medicine
- Cardiology
- Ablation
- Internal medicine
- Good health and well-being
Funding
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- AAtriCure
- BSBoston Scientific Corporation
- CMCook Medical
- AAbiomed
- ECEuropean CommissionAward: 965286
- BHBayer HealthCare
- ANAgence Nationale de la RechercheAwards: ANR-10-IAHU-04, IHU LIRYC ANR-10-IAHU-04, ANR-10, 10-IAHU-04
- SServier
- AOAOP Orphan
- MMicroPort
- BVBayer Vital
- BWBiosense Webster
- DSDaiichi Sankyo Europe